中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipeline
Overview
HCV
HBV
HIV
Partnership
Investors
Financials & Filing
Presentation Materials
News
2020
2019
2018
2017
2016
2015
2014
Careers
2020
2019
2018
2017
2016
2015
2014
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist
2020-10-12
Ascletis’ Strategic Partner Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640(ASC40) in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020
2020-10-10
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
2020-09-14
Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
2020-09-09
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen
2020-08-20
1
2
3
4
»
